Celsion Corporation to Host Conference Call and Webcast on January 31, 2013 at 8:00 AM EST to Present Top-Line Data from its

Celsion Corporation to Host Conference Call and Webcast on January 31, 2013 at
  8:00 AM EST to Present Top-Line Data from its Pivotal Phase III HEAT Study

PR Newswire

LAWRENCEVILLE, N.J., Jan. 30, 2013

LAWRENCEVILLE, N.J., Jan. 30, 2013 /PRNewswire/ -- Celsion Corporation
(NASDAQ: CLSN), a leading oncology drug development company, today announced
that it will host a conference call and webcast at 8:00 a.m. Eastern Time on
Thursday, January 31, 2013 to present the top-line results from its pivotal
Phase III HEAT Study with ThermoDox® in combination with radiofrequency
ablation (RFA) in patients with intermediate hepatocellular carcinoma (HCC)
versus those patients receiving RFA alone.

The HEAT Study, which has enrolled a total of 701 patients at 79 sites in 11
countries, has been designated as a Priority Trial for liver cancer by
theNational Institutes of Health, has received Fast Track Designation from
theFDAand has received Orphan Drug Designation in both the U.S. andEurope.

Conference Call

The conference call may be accessed by dialing 1-888-466-4462 (Toll-Free/North
America) or 1-719-457-2627 (International/Toll) and ask for the Celsion
Corporation Phase III HEAT Study Conference Call approximately 10 minutes
before the call is scheduled to begin. The call will also be broadcast live on
the internet at http://www.celsion.com.

The call will be archived for replay at 2 p.m. EST on January 31, 2013, and
will remain available until February 14, 2013. The replay can be accessed at
1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517
(International/Toll) using Conference ID: 4540212. An audio replay of the call
will also be available on the Company's website, http://www.celsion.com, for
30 days after 2 p.m. EST on Friday, January 31, 2013.

About the HEAT Study

HEAT (Hepatocellular Carcinoma Study of RFA and ThermoDox®) was an
international, multi-center, randomized, placebo-controlled study that
randomized 701 patients with intermediate (tumor size 3 cm to 7 cm),
unresectable HCC to 50mg/m^2 ThermoDox® plus RFA or RFA alone. The primary
endpoint of the study was progression-free survival, as defined by the Special
Protocol Assessment agreed to with the U.S. FDA. Safety and tolerability were
also evaluated.

The HEAT Study, the largest clinical trial to date in patients with
intermediate HCC, was conducted at 79 clinical sites around the world,
including the United States, Canada, Italy, China, Taiwan, Hong Kong, Korea,
Thailand, Malaysia and the Philippines.

About Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), also known as primary liver cancer, is
currently one of the most common and deadly forms of cancer worldwide. With
few approved treatment options, it is estimated that up to 90 percent of
unresectable (inoperable) liver cancer patients will die within five years of
diagnosis. HCC is the fourth leading cause of death from cancer and the third
most common in males. There are approximately 26,000 new cases per year in the
US and approximately 40,000 cases per year in Europe. However, HCC is rapidly
growing worldwide at approximately 750,000 cases per year, due to the high
prevalence of Hepatitis B and C in developing countries - more than 50 percent
of these new cases will be in China. HCC currently is the world's fifth
largest cancer and the World Health Organization estimates that HCC may become
the number one cancer worldwide by 2020, surpassing lung cancer.

About ThermoDox®

ThermoDox® is an investigational, proprietary heat-activated formulation of
liposomal doxorubicin, an approved and frequently used oncology drug for the
treatment of a wide range of cancers, and is currently being investigated in
clinical trials for its potential to treat patients with intermediate (tumor
size 3 to 7 cm), unresectable (inoperable) HCC. ThermoDox® is an
investigational treatment and is not approved by the FDA, EMA or other health
authorities.

ThermoDox® enhances the efficacy of doxorubicin by encapsulating it with
Celsion's proprietary lysolipid thermally sensitive liposomes (LTSL). These
heat-sensitive liposomes change structure when heated to a specific
temperature (via a heat source like RFA), creating openings in the liposome
that release doxorubicin directly into the targeted tumor and surrounding
tissue. While the RFA targets the tumor, ThermoDox® delivers higher
concentrations of chemotherapy directly to the tumor site, capturing
micrometastases (tumors too miniscule to be detected) outside of the RFA
ablation zone, which are most commonly responsible for post-treatment disease
recurrence. In animal models, ThermoDox® has been shown to deliver 25 times
more doxorubicin into tumors than intravenous doxorubicin, and five times more
doxorubicin than standard liposomal formulations of the drug. Additionally,
ThermoDox® is less permeable across normal blood vessels than free
doxorubicin, minimizing systemic toxicity.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and
commercialization of innovative cancer drugs. The company is focused on
advancing its heat-mediated, tumor-targeting drug delivery platform to address
difficult-to-treat cancers. Celsion has research, license, or
commercialization agreements with leading institutions including the National
Institutes of Health, Duke University Medical Center, University of Hong Kong,
the University of Pisa, the UCLA Department of Medicine, the Kyungpook
National University Hospital, the Beijing Cancer Hospital and the University
of Oxford. For more information on Celsion, visit our website:
http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials by others; possible acquisitions of other
technologies, assets or businesses; possible actions by customers, suppliers,
competitors, regulatory authorities; and other risks detailed from time to
time in the Company's periodic reports filed with the Securities and Exchange
Commission.

Investor Contact

Jeffrey W. Church
Sr. Vice President – Corporate
Strategy and Investor Relations
609-482-2455
jchurch@celsion.com

Media Contact

Kimberly Ryan
212-880-5289
kimberly.ryan@ogilvy.com



SOURCE Celsion Corporation

Website: http://www.celsion.com
 
Press spacebar to pause and continue. Press esc to stop.